PDL BioPharma (PDLI) Misses Q1 EPS by 2c

PDL BioPharma (NASDAQ: PDLI) reported Q1 EPS of $0.50, $0.02 worse than the analyst estimate of $0.52. Revenue for the quarter came in at $149.7 million versus the consensus estimate of $140.8 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Movano (MOVE) Misses Q2 EPS by 195c